The drug, MDV3100, works by blocking androgen receptors, which regulate gene expression. Previous treatments involved slowing down the action of androgens.
Androgens, such as testosterone, bind to androgen receptors to promote masculine characteristics. They can also, however, contribute to tumour growth.
With a higher level of androgen receptors, some tumours become unresponsive to traditional anti-androgen therapy. By shutting down the receptors, MDV3100 is thought to be a more effective way of destroying cancerous growth.
Dr. Scher reports that following treatment with the drug, both PSA levels and tumours diminished. Researchers are now waiting for FDA approval to conduct larger clinical studies with MDV3100.
For the full story: Memorial Sloan-Kettering Cancer Center. Drug Shows Activity in Men with Advanced Prostate Cancer